Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 25, 2014
Pharmacy Choice - News - U.S. Pharmaceutical Industry - October 25, 2014

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/25/14 - Bracco Diagnostics Secures FDA Approval for New Ultrasound Contrast Agent [Professional Services Close - Up]
Bracco Diagnostics recently reported that the U.S. Food and Drug Administration has approved its new ultrasound contrast agent Lumason for injectable suspension, indicated for use in adults with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
10/25/14 - Clinical trials of 2 Ebola vaccines starts,results will be available in December [Cihan News Agency (Turkey)]
Marie Paule Kieny, told reporters that the clinical trials will be conducted on the two "most advanced" vaccines and "at least 5 more vaccines" will be in the clinic in the first months of 2015. Kieny said the pharmaceutical companies developing these vaccines "are committing to ramping up the production capacity to millions of doses to be availabl
10/25/14 - First Ebola vaccines earmarked for health workers as nations speed ahead with trials: Vaccines to be tested in Liberia and Sierra Leone Drug companies promise millions of doses next year
Ebola vaccine trials are to start in west Africa in December, a month earlier than planned, and hundreds of thousands of doses will be available by mid-2015, the World Health Organisation says. The first vaccinations of health workers and others at high risk, including burial teams, are likely to take place in Liberia, with Sierra Leone not far beh
10/25/14 - Gilead: FDA Approvides Harvoni (Ledipasvir/Sofosbuvir) [Professional Services Close - Up]
Gilead Sciences recently reported that the U.S. Food and Drug Administration has approved Harvoni, a once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead Sciences reported in a release that Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor...
10/25/14 - Lundbeck presents new efficacy and safety data analyses for desmoteplase in patients with acute ischaemic stroke
Valby, Copenhagen, 2014-10-25 11:30 CEST In the per-protocol population desmoteplase was associated with better functional outcome compared to placebo as assessed by the modified Rankin Scale In additional data analyses it is suggested that magnetic resonance imaging is more sensitive than computed tomography scanning for identifying appropri
10/25/14 - Pfizer Reports Vaccine Candidate Data [Professional Services Close - Up]
Pfizer presented data from a Phase 1/ Phase 2 study evaluating the safety, tolerability and immunogenicity of a single-dose vaccine of Pfizer's investigational 4- antigen Staphylococcus aureus candidate vaccine in healthy adults. Kathrin Jansen, senior vice president of the Vaccine Research and Early Development unit for Pfizer. IDWeek 2014 is an a
10/25/14 - Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Pacira Pharmaceuticals, Inc.
By a News Reporter-Staff News Editor at Investment Weekly News Rigrodsky& Long, P.A.: Do you, or did you, own shares of Pacira Pharmaceuticals, Inc.? Rigrodsky& Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, announces that a complaint has been filed in the United States District Court for the District o
10/25/14 - The politics of dehumanization
The outbreak of the deadly Ebola virus in West Africa that has killed thousands of people so far has only become an issue of concern since reports of individuals from the West being infected with the disease have surfaced. Stephen Hall, a CEO of a pharmaceutical company explains why: "Traditional investors have not been enthusiastic about funding t
10/24/14 - "Methods of Administering Drugs in an Implantable Multi-Chamber Pump" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Gibson, Susan P.; Vanhove, Geertrui F., filed on March 27, 2014, was made available online on October 9, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Jazz Pharmaceuticals,
10/24/14 - AbbVie's HUMIRA adalimumab Receives U.S. FDA Approval for Extension of Polyarticular Juvenile Idiopathic Arthritis Indication to Patients Ages 2 and...
AbbVie's HUMIRA adalimumab Receives U.S. By a News Reporter-Staff News Editor at Health& Medicine Week AbbVie announced that the U.S. Food and Drug Administration has approved the extension of the HUMIRA indication for moderately to severely active polyarticular juvenile idiopathic arthritis to reducing signs and symptoms in patients ages 2 an
In the U.S., the FDA has accepted for priority review the Biologics License Application for previously treated advanced melanoma and the Prescription Drug User Fee Act goal date for a decision is March 30, 2015. The FDA also granted Opdivo Breakthrough Therapy Designation for this indication. During the third quarter of 2014, the Company and Pfizer
10/24/14 - Chinese Patent Medicine Market Trends Analysis and 2018 Forecasts adds Research and Development Trend Forecast of Chinese Patent Medicine in China, 2014-2018 market report to the pharmaceuticals category of its online industry research reports library. It analyses the policy environment, market scale, competition pattern, development trend and key enterprises in Chinese patent medicine...
THIRD QUARTER 2014 (JUL SEP) ? Net sales in the quarter amounted to SEK 22.4 (16.8) million, corresponding to an increase of 34 percent. ? Net sales for consumables in the quarter amounted to SEK 21.0 (16.8) million, corresponding to an increase of 25 percent in SEK. Sales for consumables increased by 18 percent in local currency. ? Ope
10/24/14 - Covidien Announces U.S. Food and Drug Administration 510k Clearance for Nellcor? Portable SpO2 Patient Monitoring System
By a News Reporter-Staff News Editor at Health& Medicine Week Covidien plc announced U.S. Food and Drug Administration 510 clearance for the Nellcor? Portable SpO2 Patient Monitoring System. Part of a comprehensive Covidien respiratory function monitoring portfolio, this convenient, handheld patient monitor is simple to use and ideal for fast,
10/24/14 - Cydex Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Oct. 24 Cydex Pharmaceuticals, Lenexa, Kansas, has been assigned a patent developed by six co-inventors for "formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use." The co-inventors are Karen T. Johnson, Lawrence, Kansas, Rebecca L. Wedel, Lawrence, Kansas, Stephen G. Machatha, Overland Park, Ka
10/24/14 - DARA BioSciences Supports to Increase Awareness and Raise Funds to Fight Breast Cancer
DARA BioSciences, Inc., an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced it is supporting with its Sponsor level...
10/24/14 - Elite Pharmaceuticals Announces New Management Appointments
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Dr. Smith previously held the positions of Chief Intellectual Property Counsel for Alpharma, Inc. and before that Head of North American Intellectual Proper
10/24/14 - FDA Approves New Treatment for Rare Form of Hemophilia
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. The U.S. Food and Drug Administration yesterday approved Obizur for the treatment of bleeding episodes in adults with acquired hemophilia A. "The approval of this product provides an important therapeutic option for use in the care of
10/24/14 - Icahn School of Medicine at Mount Sinai opens genomics research facility in Branford [New Haven Register, Conn.]
Oct. 24 BRANFORD Connecticut's reputation as a center for biomedical research received a boost Thursday with an announcement that the Icahn School of Medicine at Mount Sinai has opened a state-of-the-art genomics research facility on Commercial Street. "We are investing in industry leaders like the Icahn School of Medicine at Mount Sinai so th
10/24/14 - Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting
Imprimis Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today reported on clinical findings demonstrating the safety and benefits of Dropless cataract surgery and provided an update resulting from the recent American...
10/24/14 - Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production
Release date- 22102014- New Brunswick, N.J- Johnson& Johnson today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. The vaccine regimen, which was discovered in a collaborative research program with
10/24/14 - Kimberly-Clark Sterilization Wrap Is Now Most Validated On The Market; First and Only Sterilization Wrap Manufacturer to Receive FDA Clearance for All Standard Sterilization Methods in North America
Release date- 23102014- ROSWELL, Ga- Kimberly-Clark Health Care, soon to be Halyard Health, announced today that it is the first and only manufacturer to receive 510 clearance from the U.S. Food and Drug Administration for use of their sterilization wrap portfolio with all standard sterilization modalities. 'Providing innovation in sterilization te
10/24/14 - Lundbeck Provides Update on New Drug Application for Intravenous Carbamazepine
Lundbeck LLC announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Carbella? injection, an investigational intravenous formulation of the anti-epileptic drug carbamazepine. Lundbeck is currently addressing requests specified in the letter, and is
10/24/14 - Minnesota Marathon Runner with Cancer - Don Wright - Joins Inaugural Effort to Accelerate Access to New Medicines for People Who Are Critically Ill
Minnesota native Don Wright, who has completed 84 marathons in the last 11 years all of them with multiple myeloma will be a featured participant in the inaugural event of a new partnership fighting to accelerate access to new medications for cancer patients. The Minneapolis event is a partnership created by the Richard Schulze Foundation, es
10/24/14 - Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe
Tumor BRACAnalysis CDx Will Identify More Patients for Treatment With PARP Inhibitors SALT LAKE CITY and ZURICH, Oct. 24, 2014 Myriad Genetics, Inc. today announced it has established a Tumor BRACAnalysis CDx laboratory in Europe. Earlier today, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing..
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


The Diversion of Controlled Substances and the Law
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement